Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. ACN
9. COHR
10. META

Go back to Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 219.07 +3.57 (1.66%)
Previous Close $215.50    52 Week High $333.65 
Open $216.14    52 Week Low $223.02 
Day High $221.92    P/E 28.05 
Day Low $214.59    EPS $7.81 
Volume 928,562       

Sagebrush Gold Ltd. (NASDAQ: SAGE) Delayed: 8.68 --0 (-0%)
Previous Close $8.68    52 Week High $62.64 
Open $8.68    52 Week Low $26.28 
Day High $8.68    P/E N/A 
Day Low $8.68    EPS $-0.94 
Volume 242,929